RT Journal Article
SR Electronic
T1 EPIDEMIOLOGICAL AND CLINICAL CHARACTERISTICS OF COVID-19 PATIENTS IN KENYA
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.09.20228106
DO 10.1101/2020.11.09.20228106
A1 Ombajo, Loice Achieng
A1 Mutono, Nyamai
A1 Sudi, Paul
A1 Mutua, Mbuvi
A1 Sood, Mohammed
A1 Ali Loo, Alliy Muhammad
A1 Juma, Phoebe
A1 Odhiambo, Jackline
A1 Shah, Reena
A1 Wangai, Frederick
A1 Maritim, Marybeth
A1 Anzala, Omu
A1 Amoth, Patrick
A1 Kamuri, Evans
A1 Munyu, Waweru
A1 Thumbi, SM
YR 2020
UL http://medrxiv.org/content/early/2020/11/12/2020.11.09.20228106.abstract
AB Background More than 49,000 cases of infection and 900 deaths from COVID-19 have been recorded in the Kenya. However, the characteristics and risk factors for severe outcomes among hospitalized COVID-19 patients in this setting have not been described.Methods We extracted demographic, laboratory, clinical and outcome data from medical records of RT-PCR confirmed SARS-CoV2 patients admitted in six hospitals in Kenya between March and September, 2020. We used Cox proportional hazards regressions to determine factors related to in-hospital mortality.Results Data from 787 COVID-19 patients was available. The median age was 43 years (IQR 30-53), with 505 (64%) males. At admission, 455 (58%) were symptomatic. The commonest symptoms were cough (337, 43%), loss of taste or smell (279, 35%), and fever (126, 16%). Co-morbidities were reported in 340 (43%), with cardiovascular disease, diabetes and HIV documented in 130 (17%), 116 (15%), 53 (7%) respectively. 90 (11%) were admitted to ICU for a mean of 11 days, 52 (7%) were ventilated with a mean of 10 days, 107 (14%) died. The risk of death increased with age [hazard ratio (HR) 1.57 (95% CI 1.13 – 2.19)] for persons >60 years compared to those <60 years old; having co-morbidities [HR 2.34 (1.68 – 3.25)]; and among males [HR 1.76 (1.27, 2.44)] compared to females. Elevated white blood cell count and aspartate aminotransferase were associated with higher risk of death.Conclusions We identify the risk factors for mortality that may guide stratification of high risk patients.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://osf.io/b6wkr/ Funding StatementNo funding was received for this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received ethical approval from the Kenyatta National Hospital-University of Nairobi Ethics and Research Committee (approval number P223/03/2020. There was waiver of consent for data extraction from charts.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified participant data is available and will be made publicly available 6 months after publication of this manuscript or earlier for related work https://osf.io/b6wkr/